INTRODUCTION AND OBJECTIVES: Malignant pheochromocytomas (MP) are a rare form of endocrine malignancy which can occur in familial and sporadic clinical settings. We performed comprehensive genomic profiling (CGP) to characterize the genomic alterations (GA) in MP and to enable the search for potential therapy targets.
INTRODUCTION AND OBJECTIVES: Malignant pheochromocytomas (MP) are a rare form of endocrine malignancy which can occur in familial and sporadic clinical settings. We performed comprehensive genomic profiling (CGP) to characterize the genomic alterations (GA) in MP and to enable the search for potential therapy targets.
METHODS: From a series of 181,782 consecutive clinical cases, 43 cases of clinically advanced MP underwent CGP using a hybrid-capture based commercial assay to evaluate all classes of GA. Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and reported as mutations/Mb and microsatellite instability (MSI) was determined on 114 loci. IHC for PD-L1 expression was performed on a subset of patients (DAKO 22C3 antibody).
RESULTS: All patients had clinically advanced recurrent and/or metastatic disease. There were 33 (77%) of MP known to have originated in the adrenal gland and 10 (23%) of the MP were sequenced from metastatic site. The primary tumor was used for sequencing in 13 (30%) of the MP cases and a non-primary tumor metastatic site (liver, lung, bone, soft tissue, lymph node, kidney, peritoneal cavity, and chest wall) in 30 (70%) of the MP cases. There were 2.3 GA/tumor. The most frequent un-targetable GA were ATRX (26%), TP53 (21%), SDHB (11%), CTNNB1 (7%), VHL (7%), and CDKN2A/2B, PIK3R2, NOTCH2 and MEN1 (all 5%). The most frequent potentially targetable GA included RET (9%), NF1 (9%) and FGFR1 (5%). PBRM1 GA were found in 2% of MAP. Germline mutations in known cancer predisposition genes were predicted in 7 (16%) of cases involving SDHB (4 cases) and BRCA1, MEN1, and MSH2 (1 case each). The mean TMB was 2.95 mutations/Mb, the median TMB was 2.4 mutations/Mb. 0 (0%) of 33 MP evaluated for MSI had a MSI-High status.
CONCLUSIONS: MP represent a rare form of endocrine cancer that feature a variety of genomic alterations. Although the GA/tumor is relatively low for MP, CGP can reveal important potential targets for therapy in the metastatic setting including RET, NF1 and FGFR1. MAP do not reveal strong potential for immunotherapy with low TMB, absence of MSI-High status and low (2%) PBRM1 mutation frequencies. Based on this data, further study of CGP as a method of developing precision therapies for MP appears warranted.
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MP69-10 PROGNOSIS OF ADULT ADRENAL NEUROBLASTOMA AND CONDITIONAL PROBABILITY SURVIVAL ANALYSIS BASED UPON POPULATION LEVEL
Wenjun Xiao*, Yao Zhu, Dingwei Ye, Yuanyuan Qu, Jun Wang, Shanghai, China, People's Republic of METHODS: The SEER database was queried for patients diagnosed with adrenal neuroblastoma. The cases aging !14 years old at diagnosis or surviving over 14 years old were selected. Clinical and pathologic information were collected as well as survival status as of December 31, 2014. Cases with unavailable follow-up information were excluded. CS was defined as the probability of surviving for an additional period on the condition that a patient had already survived for a designated length of time.Survival analysis were performed. CS(y/x), is the probability of surviving an additional y years, S(xþy), given that the patient has already survived x years S(x): CS(y/x)[S(xþy)/S(x).
RESULTS: A total of 454 patients were selected, and 55 cases aged !14 years old at diagnosis while 399 cases survived over 14 years old. The gender ratio was 1.2 male to 1 female, and the number of left and right proportion was 1.5:1. Factors associated with higher overall mortality were older age at diagnosis and diagnosed with distant metastases. Age at diagnosis was the most important prognostic factors. Patients diagnosed at age of !14 years old had the median disease-specific survival (DSS) of 117 months. In the subgroup surviving over 14 years old, patients diagnosed at age of >5 years had a 5-year conditional DSS rate of 71.2% at the time point of 14 years old, which was significantly less than that of patients diagnosed at age of 5 years old (99.7%). So we further compared the subgroup aging from 5 to 14 years at diagnosis and surviving over 14 years old (Figure a blue) with the subgroup aging !14 years at diagnosis (Figure a red) . The gains in 5-year conditional DSS over time were more pronounced in patients with older age at diagnosis, resulting in the decrease of the differences of conditional DSS between the different groups (Figure b) . CONCLUSIONS: These findings provided a new perspective for understanding the prognosis of adrenal NB. The age at diagnosis play a very important role even for the patients surviving over 14 years old. METHODS: ACC patients who were treated by surgery from December 2007 to December 2017 at west China hospital of sichuan university, people's hospital of gansu province and lanzhou military region general hospital were selected as subjects, and blood routine examination results and clinical and pathological data were collected within one week before surgery.The optimal truncation value of preoperative ptc-8 was determined by x-tile software and the patients were divided into groups with high ptc-8 values (476.2nmol/L>) and low ptc-8 values (<476.2nmol/L).To observe the general pathological data of high and low ptc-8 groups, kaplan-meier method was used to draw the survival curve, and univariate and multivariate Cox regression were used to explore the factors influencing the prognosis of ACC patients.
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RESULTS: We found that the overall survival time (OS) of patients in the high ptc-8 value group was shorter than that in the low ptc-8 value group (P[0.014) CONCLUSIONS: The preoperative serum cortisol concentration of 8:00 AM is an independent risk factor for the prognosis of ACC. Preoperative ptc-8 can be used as one of the important indexes for the evaluation of OS after ACC, which is expected to predict the prognosis risk of patients after ACC.
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INTRODUCTION AND OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare but deadly malignancy with a high rate of recurrence. Surgery remains the only potentially curative option for ACC, while its role for recurrent disease is controversial. We summarized the outcomes of patients with recurrent ACC in our hospital.
METHODS: This study retrospectively reviewed all patients with recurrent ACC, managed in our institution between 2009 and 2017. All available clinicopathologic data and follow-up outcomes were collected. Kaplan-Meier method and Cox proportional hazards model were used to evaluated survival outcome according to treatment for recurrent disease.
RESULTS: Thirty-four cases were included. Twelve patients underwent reoperation for recurrence, while 22 had nonoperative therapy. Baseline patient characteristics (age, gender, hormonal secretion, tumor stage Ki-67%, and Weiss score) were similar
